Cabıoğlu, N. Et Al. 2024. Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study. CANCER RESEARCH , vol.84, no.9_Supplement , 1.

Cabıoğlu, N., Karanlik, H., Gulcelik, M. A., Kocer, H. B., Muslumanoglu, M., İgci, A., ... Tukenmez, M.(2024). Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study. CANCER RESEARCH , vol.84, no.9_Supplement, 1.

Cabıoğlu, Neslihan Et Al. "Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study," CANCER RESEARCH , vol.84, no.9_Supplement, 1, 2024

Cabıoğlu, Neslihan Et Al. "Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study." CANCER RESEARCH , vol.84, no.9_Supplement, pp.1, 2024

Cabıoğlu, N. Et Al. (2024) . "Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study." CANCER RESEARCH , vol.84, no.9_Supplement, p.1.

@article{article, author={Neslihan Cabıoğlu Et Al. }, title={Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study}, journal={CANCER RESEARCH}, year=2024, pages={1} }